LiU Invest invests in Glycobond

Additional investment

LiU Invest further invests in Glycobond. Glycobond has developed a method to analyze the occurrence of early liver cancer among patients with different types of liver disease, such as hepatitis. Early diagnosis makes it possible to effectively treat patients with surgery or drug treatment.

"We have previously invested in Glycobond in installments. The company can demonstrate good development and a strong team, and then it becomes natural to continue investing in the company," says Jonas Nilsson, LiU Invest.

For more information see: www.glycobond.com